4 research outputs found
Discovery of the First Potent and Orally Available Agonist of the Orphan G‑Protein-Coupled Receptor 52
G-protein-coupled receptor 52 (GPR52)
is an orphan Gs-coupled G-protein-coupled
receptor. GPR52 inhibits dopamine D<sub>2</sub> receptor signaling
and activates dopamine D<sub>1</sub>/<i>N</i>-methyl-d-aspartate receptors via intracellular cAMP accumulation, and
therefore, GPR52 agonists may have potential as a novel class of antipsychotics.
A series of GPR52 agonists with a bicyclic core was designed to fix
the conformation of the phenethyl ether moiety of compounds <b>2a</b> and <b>2b</b>. 3-[2-(3-Chloro-5-fluorobenzyl)-1-benzothiophen-7-yl]-<i>N</i>-(2-methoxyethyl)Âbenzamide <b>7m</b> showed potent
activity (pEC<sub>50</sub> = 7.53 ± 0.08) and good pharmacokinetic
properties. Compound <b>7m</b> significantly suppressed methamphetamine-induced
hyperactivity in mice after oral administration of 3 mg/kg without
disturbance of motor function
Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach
On the basis of a
superposition study of X-ray crystal structures
of complexes of quinazoline derivative <b>1</b> and triazole
derivative <b>2</b> with matrix metalloproteinase (MMP)-13 catalytic
domain, a novel series of fused pyrimidine compounds which possess
a 1,2,4-triazol-3-yl group as a zinc binding group (ZBG) was designed.
Among the herein described and evaluated compounds, <b>31f</b> exhibited excellent potency for MMP-13 (IC<sub>50</sub> = 0.036
nM) and selectivities (greater than 1,500-fold) over other MMPs (MMP-1,
-2, -3, -7, -8, -9, -10, and -14) and tumor necrosis factor-α
converting enzyme (TACE). Furthermore, the inhibitor was shown to
protect bovine nasal cartilage explants against degradation induced
by interleukin-1 and oncostatin M. In this article, we report the
discovery of extremely potent, highly selective, and orally bioavailable
fused pyrimidine derivatives that possess a 1,2,4-triazol-3-yl group
as a novel ZBG for selective MMP-13 inhibition
Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists
Benzazole derivatives with a flexible
aryl group bonded through
a one-atom linker as a new scaffold for a corticotropin-releasing
factor 1 (CRF<sub>1</sub>) receptor antagonist were designed, synthesized,
and evaluated. We expected that structural diversity could be expanded
beyond that of reported CRF<sub>1</sub> receptor antagonists. In a
structure–activity relationship study, 4-chloro-<i>N</i><sup>2</sup>-(4-chloro-2-methoxy-6-methylphenyl)-1-methyl-<i>N</i><sup>7</sup>,<i>N</i><sup>7</sup>-dipropyl-1<i>H</i>-benzimidazole-2,7-diamine <b>29g</b> had the most
potent binding activity against a human CRF<sub>1</sub> receptor and
the antagonistic activity (IC<sub>50</sub> = 9.5 and 88 nM, respectively)
without concerns regarding cytotoxicity at 30 μM. Potent CRF<sub>1</sub> receptor-binding activity in brain in an ex vivo test and
suppression of stress-induced activation of the hypothalamus–pituitary–adrenocortical
(HPA) axis were also observed at 138 μmol/kg of compound <b>29g</b> after oral administration in mice. Thus, the newly designed
benzimidazole <b>29g</b> showed in vivo CRF<sub>1</sub> receptor
antagonistic activity and good brain penetration, indicating that
it is a promising lead for CRF<sub>1</sub> receptor antagonist drug
discovery research
Optimization of (2,3-Dihydro-1-benzofuran-3-yl)acetic Acids: Discovery of a Non-Free Fatty Acid-Like, Highly Bioavailable G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist as a Glucose-Dependent Insulinotropic Agent
G protein-coupled receptor 40 (GPR40)/free fatty acid
receptor
1 (FFA1) is a free fatty acid (FFA) receptor that mediates FFA-amplified
glucose-stimulated insulin secretion in pancreatic β-cells.
We previously identified (2,3-dihydro-1-benzofuran-3-yl)Âacetic acid
derivative <b>2</b> as a candidate, but it had relatively high
lipophilicity. Adding a polar functional group on <b>2</b> yielded
several compounds with lower lipophilicity and little effect on caspase-3/7
activity at 30 μM (a marker of toxicity in human HepG2 hepatocytes).
Three optimized compounds showed promising pharmacokinetic profiles
with good in vivo effects. Of these, compound <b>16</b> had
the lowest lipophilicity. Metabolic analysis of <b>16</b> showed
a long-acting PK profile due to high resistance to β-oxidation.
Oral administration of <b>16</b> significantly reduced plasma
glucose excursion and increased insulin secretion during an OGTT in
type 2 diabetic rats. Compound <b>16</b> (TAK-875) is being
evaluated in human clinical trials for the treatment of type 2 diabetes